References
1.Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol . 2015;22 Suppl 1:1-6.
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474-9.
3.Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO) EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2020.
4.Mottet N, Bellmunt J, Bolla M, et. al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol . 2017; 71(4):618-629.
5.D’Elia C, Cerruto MA, Cioffi A, et al. Upgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy.Mol Clin Oncol . 2014; 2(6):1145-1149
6.Capitanio U, Scattoni V, Freschi M, et al. Radical prostatectomy for incidental (stage T1aT1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Eur Urol . 2008;54: 118-25
7.Abedi AR, Fallah-Karkan M, Allameh F, Ranjbar A, Shadmehr A. Incidental prostate cancer: a 10-year review of a tertiary center, Tehran, Iran. Res Rep Urol . 2018;10: 1-6.
8.Rosenhammer B, Lausenmeyer EM, Mayr R, Burger M, Eichelberg C. Holmium Laser Enucleation of the Prostate Provides Similar Incidental Prostate Cancer Detection Rates as Open Prostatectomy: A Matched Pair Analysis. Urol. Int. 2018;101(4):382-386.
9.Long RM, Thomas AZ, Browne C. et al. A 30-year experience of Millin’s retropubic prostatectomy: Has this classic operation derived by a President of the College in Ireland stood the test of time? Ir J Med Sci . 2015; 184(2):341-4.
10.Capogrosso P, Capitanio U, Vertosick EA, et al. Temporal Trend in Incidental Prostate Cancer Detection at Surgery for Benign Prostatic Hyperplasia. Urology . 2018; 122: 152-7.
11.Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112(17):2735-52.
12.Richie JP, Catalona WJ, Ahmann FR, et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology . 1993; 42(4):365-74.
13.Yoo C, Oh CY, Kim SJ, et al. Preoperative clinical factors for diagnosis of incidental prostate cancer in the era of tissue-ablative surgery for benign prostatic hyperplasia: a Korean multi-center review.Korean J Urol . 2012; 53(6):391–395.
14.Antunes AA, Freire Gde C, Aiello Filho D, Cury J, Srougi M. Analysis of the risk factors for incidental carcinoma of the prostate in patients with benign prostatic hyperplasia. Clinics (Sao Paulo) . 2006; 61(6):545-50.
15. Laukkanen JA, Laaksonen DE, Niskanen L, et al. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev. 2004; 13(10):1646-50.
16. Kayali M, Balci M, Aslan Y, et al. The relationship between prostate cancer and presence of metabolic syndrome and late-onset hypogonadism.Urology . 2014; 84(6):1448-52.
17. Xiang YZ, Xiong H, Cui ZL, et al. The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. J Exp Clin Cancer Res . 2013; 32(1):9.
18.Catalona WJ, Richie JP, Ahmann FR. Et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol . 1994; 151(5):1283-90.
19.Sakamoto H, Matsumoto K, Hayakawa N, et al. Preoperative parameters to predict incidental (T1a and T1b) prostate cancer. Can Urol Assoc J . 2014; 8(11-12):E815-20.
20.Zhou J, He Z, Ma S, Liu R. AST/ALT ratio as a significant predictor of the incidence risk of prostate cancer. Cancer Med . 2020; 9(15):5672-5677.
21.Wang H, Gu L, Wu Y, et al. The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6. BMC Cancer. 2017; 17(1):629.